Oseltamivir carboxylate HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581033

CAS#: 1415963-60-8 (HCl)

Description: Oseltamivir carboxylate is an active metabolite of oseltamivir phosphate (Tamiflu).

Chemical Structure

Oseltamivir carboxylate HCl
CAS# 1415963-60-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 581033
Name: Oseltamivir carboxylate HCl
CAS#: 1415963-60-8 (HCl)
Chemical Formula: C14H25ClN2O4
Exact Mass:
Molecular Weight: 320.81
Elemental Analysis: C, 52.41; H, 7.86; Cl, 11.05; N, 8.73; O, 19.95

Price and Availability

Size Price Availability Quantity
10.0mg USD 295.0 2 Weeks
50.0mg USD 850.0 2 Weeks
100.0mg USD 1250.0 2 Weeks
Bulk inquiry

Related CAS #: 1415963-60-8 (HCl)   187227-45-8 (free)    

Synonym: Oseltamivir carboxylate hydrochloride, Oseltamivir carboxylate HCI, Oseltamivir carboxylate(HCI), Ro 64-0802 hydrochloride, GS4071 HC.

IUPAC/Chemical Name: (3R,4R,5S)-4-Acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylic acid hydrochloride


InChi Code: InChI=1S/C14H24N2O4.ClH/c1-4-10(5-2)20-12-7-9(14(18)19)6-11(15)13(12)16-8(3)17;/h7,10-13H,4-6,15H2,1-3H3,(H,16,17)(H,18,19);1H/t11-,12+,13+;/m0./s1

SMILES Code: O=C(C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1)O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 320.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: K R, V S. Discovery of Potent Neuraminidase Inhibitors Using a Combination of Pharmacophore-Based Virtual Screening and Molecular Simulation Approach. Appl Biochem Biotechnol. 2017 Oct 23. doi: 10.1007/s12010-017-2625-y. [Epub ahead of print] PubMed PMID: 29063410.

2: Andreatos N, Mylonakis E. Triple therapy reduced mortality more than oseltamivir alone in patients admitted for severe influenza infection. Ann Intern Med. 2017 Oct 17;167(8):JC41. doi: 10.7326/ACPJC-2017-167-8-041. PubMed PMID: 29049760.

3: Choi WS, Jeong JH, Kwon JJ, Ahn SJ, Lloren KKS, Kwon HI, Chae HB, Hwang J, Kim MH, Kim CJ, Webby RJ, Govorkova EA, Choi YK, Baek YH, Song MS. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6 and N8 Neuraminidase Subtypes. J Virol. 2017 Oct 18. pii: JVI.01580-17. doi: 10.1128/JVI.01580-17. [Epub ahead of print] PubMed PMID: 29046464.

4: Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S, Zhang L, Chen J, Cao J, Bi X, Anderson SF, Alefantis T, Zhang M, Cai X, Yang K, Zheng Q, Fang M, Yu H, Luo W, Zheng Z, Yuan Q, Zhang J, Wai-Kuo Shih J, Kleanthous H, Chen H, Chen Y, Xia N. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med. 2017 Oct 18;9(412). pii: eaam5752. doi: 10.1126/scitranslmed.aam5752. PubMed PMID: 29046433.

5: Al-Tawfiq JA, Rabaan AA, Hinedi K. Influenza is more common than Middle East Respiratory Syndrome Coronavirus (MERS-CoV) among hospitalized adult Saudi patients. Travel Med Infect Dis. 2017 Oct 12. pii: S1477-8939(17)30159-X. doi: 10.1016/j.tmaid.2017.10.004. [Epub ahead of print] PubMed PMID: 29031867.

6: Hernu R, Chroboczek T, Madelaine T, Casalegno JS, Lina B, Cour M, Argaud L; On behalf the “Flu in Lyon ICUs” Study Group. Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis. Intensive Care Med. 2017 Oct 12. doi: 10.1007/s00134-017-4953-3. [Epub ahead of print] PubMed PMID: 29026934.

7: Deng Y, Li C, Han J, Wen Y, Wang J, Hong W, Li X, Liu Z, Ye Q, Li J, Zhou C, Yu L, Qin C, Zhang F, Jiang T. Phylogenetic and genetic characterization of a 2017 clinical isolate of H7N9 virus in Guangzhou, China during the fifth epidemic wave. Sci China Life Sci. 2017 Oct 9. doi: 10.1007/s11427-017-9152-1. [Epub ahead of print] PubMed PMID: 29019145.

8: Cho J, Yi H, Jang EY, Lee MS, Lee JY, Kang C, Lee CH, Kim K. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. Biochem Biophys Res Commun. 2017 Oct 7. pii: S0006-291X(17)32007-7. doi: 10.1016/j.bbrc.2017.10.037. [Epub ahead of print] PubMed PMID: 29017920.

9: Huang SY, Huang WC, Chen YC, Tsai CY, Lee IK. Increased Mortality in Seasonal H3N2 Patients Compared with those with Pandemic 2009 H1N1 in Taiwan, 2009-2010. Am J Trop Med Hyg. 2017 Sep 25. doi: 10.4269/ajtmh.17-0172. [Epub ahead of print] PubMed PMID: 29016325.

10: Gauer R, Hu C, Beaman L. Fever, rash, and leukopenia in a 32-year-old man • Dx? J Fam Pract. 2017 Oct;66(10):E7-E10. PubMed PMID: 28991941.

11: Yoshida T, Fukami T, Kurokawa T, Gotoh S, Oda A, Nakajima M. Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans. Eur J Pharm Sci. 2017 Sep 28;111:167-176. doi: 10.1016/j.ejps.2017.09.040. [Epub ahead of print] PubMed PMID: 28966098.

12: Gu P, Fan X, Liang Q, Qi Q, Li Q. Novel technologies combined with traditional metabolic engineering strategies facilitate the construction of shikimate-producing Escherichia coli. Microb Cell Fact. 2017 Sep 29;16(1):167. doi: 10.1186/s12934-017-0773-y. Review. PubMed PMID: 28962609; PubMed Central PMCID: PMC5622527.

13: Doll MK, Winters N, Boikos C, Kraicer-Melamed H, Gore G, Quach C. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017 Aug 22. doi: 10.1093/jac/dkx271. [Epub ahead of print] PubMed PMID: 28961794.

14: Enkhtaivan G, Muthuraman P, Kim DH, Mistry B. Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. Bioorg Med Chem. 2017 Oct 15;25(20):5185-5193. doi: 10.1016/j.bmc.2017.07.006. Epub 2017 Jul 13. PubMed PMID: 28958846.

15: Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017 Sep 22. pii: S1473-3099(17)30476-0. doi: 10.1016/S1473-3099(17)30476-0. [Epub ahead of print] PubMed PMID: 28958678.

16: Hahn J, Choi JH, Chang MJ. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J Clin Pharm Ther. 2017 Sep 25. doi: 10.1111/jcpt.12636. [Epub ahead of print] Review. PubMed PMID: 28948652.

17: Popkin DL, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R, Griffith A, Mukherjee PK, Ghannoum MA, Esper F. Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses in vitro and in vivo. Pathog Immun. 2017;2(2):252-269. doi: 10.20411/pai.v2i2.200. Epub 2017 Jun 26. PubMed PMID: 28936484; PubMed Central PMCID: PMC5605151.

18: Gubareva LV, Sleeman K, Guo Z, Yang H, Hodges E, Davis CT, Baranovich T, Stevens J. Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins. J Infect Dis. 2017 Sep 15;216(suppl_4):S566-S574. doi: 10.1093/infdis/jiw625. PubMed PMID: 28934455.

19: Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques. J Infect Dis. 2017 Sep 1;216(5):582-593. doi: 10.1093/infdis/jix296. PubMed PMID: 28931216.

20: Liu Y, Mu W, Xiao W, Wei BL, Wang L, Liu XQ, Xiong XD, Huang XM, Zhang YQ, Chen HM, Yan FJ, Tan YP, Huang YH. Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial. Oncotarget. 2017 Jul 13;8(33):55176-55186. doi: 10.18632/oncotarget.19220. eCollection 2017 Aug 15. PubMed PMID: 28903411; PubMed Central PMCID: PMC5589650.